This opportunity is no longer accepting applications.
grant RFA-NS-24-037

Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed)

This funding opportunity supports the development of genome editing therapies for Alzheimer's-related dementias (ADRD). It focuses on improving promising therapeutic leads, preparing them for further studies needed before clinical trials. The goal is to optimize candidates with proven effectiveness, ability to be manufactured, distributed in the body, and effectively engage targets. The grant …

This Notice of Funding Opportunity (NOFO) supports the optimization of promising genome editing-based therapeutic leads for Alzheimer's Disease-Related Dementias (ADRD), towards IND-enabling studies. Specifically, it supports the characterization and optimization of therapeutic lead(s) that show…

Funding Source

Agency: National Institutes of Health
Sub-agency: National Institute of Neurological Disorders and Stroke
Program: SBIR

Awards & funding

Award Ceiling: $1M
Award Amount: $1M

Dates

Opportunity Released: August 13, 2024
Open for Submission: August 13, 2024
Submission Deadline: November 19, 2024
Application Window Closes: November 19, 2024

Supporting links

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.